Awiqli (Insulin Icodec)

Insulin icodec is a long-lasting insulin for adults with type 2 diabetes. It is given as a shot under the skin just once a week. It works by slowly releasing insulin all week long to keep blood sugar steady.

Brand names:Awiqli
Medication

What people taking Awiqli (Insulin Icodec) report

Every report comes from a Lived member, sent anonymously.

Have you tried Awiqli (Insulin Icodec) for Type 2 Diabetes?

NameHow it went

About Awiqli (Insulin Icodec)

What It's For

Insulin icodec, sold as Awiqli, is a long-acting insulin injected once a week instead of once a day. In the US it is approved, along with diet and exercise, to improve blood sugar control in adults with type 2 diabetes. The FDA approved it in 2026. It is a basal insulin, meaning it supplies the steady background insulin the body needs between meals and overnight rather than covering food at mealtimes. It can be a first insulin for someone whose blood sugar is no longer controlled by pills or a GLP-1 medicine (a class of diabetes medicines that includes semaglutide, sold as Ozempic), or it can replace a daily basal insulin such as Lantus (insulin glargine) or Tresiba (insulin degludec). Some people use mealtime insulin alongside it. It is not approved for children, and in the US it is not approved for type 1 diabetes.

How It Works

Insulin is the hormone that moves sugar from the blood into muscle and fat cells and tells the liver to stop releasing stored sugar. In type 2 diabetes the body makes too little insulin, responds to it poorly, or both, so blood sugar runs high. Once insulin icodec reaches the body's insulin receptors, it has the same effects as the body's own insulin. What sets it apart is how long it lasts. After injection it binds loosely to albumin, a protein that circulates in the blood, creating a reservoir that releases active insulin slowly. Its half-life (the time it takes the body to clear half of a dose) is about one week, so a single dose keeps lowering blood sugar steadily until the next one. The same long action means it takes two to four weeks of regular doses to reach a steady level, and its effect fades slowly, which matters when blood sugar runs low.

Dosage & Administration

Awiqli comes in a prefilled FlexTouch pen and is injected under the skin of the thigh, upper arm or abdomen once a week, on the same day each week. The pen holds concentrated insulin (700 units per milliliter, labeled U-700) and dials in steps of 10 units. The dose counter shows the actual units to inject, so no conversion is needed. Never draw insulin out of the pen with a syringe, because that can lead to a large overdose. Weekly doses are much bigger numbers than daily doses, which makes errors a real risk. Serious low blood sugar needing hospital care has happened after mix-ups with another insulin or another weekly diabetes injection, a wrong dose selection, or injecting more often than once a week. Check the pen label and the dose counter before every injection. People with vision problems should have help from someone trained to use the pen. Someone new to insulin usually starts at 70 units a week, with the dose adjusted from blood sugar readings. Switching from a daily basal insulin follows a set plan: the first weekly dose, taken the day after the last daily dose, is a one-time larger dose (about one and a half times the weekly equivalent), and from the second week the dose matches the weekly equivalent before being adjusted. Blood sugar is checked more often during the switch, and mealtime insulin or other diabetes medicines may need changes too. A missed dose can be taken up to 4 days late, and the weekly schedule then restarts from that day. If more than 4 days have passed, skip it and take the next dose on the usual day. Check blood sugar more often after a missed dose, and do not inject Awiqli while blood sugar is low; treat the low first. Because each dose lasts so long, the weekly dose is not changed for a brief illness or a short-term change in eating or exercise; the care team may suggest other steps instead, such as extra glucose or changes to other diabetes medicines. Do not inject it into a vein or muscle, use it in an insulin pump, or mix it with another insulin. Rotate injection spots within an area and avoid skin that is pitted, thickened or lumpy. Unused pens are stored in the refrigerator and must never be frozen. A pen can be kept at room temperature (below 86°F), but its total time out of the refrigerator, before and during use, should not exceed 12 weeks.

Side Effects

Low blood sugar (hypoglycemia) is the most common side effect, as with any insulin. For most people with diabetes, low means a reading under 70 mg/dL, though the care team may set a different number. Signs include shakiness, sweating, hunger, a fast heartbeat, dizziness, headache, blurred vision, irritability and confusion. A mild low is treated right away with fast-acting sugar, such as glucose tablets or juice, following the care plan. Because Awiqli works for a whole week, recovery from a low can be slower than with shorter-acting insulin, so blood sugar may need rechecking and more carbohydrate afterward. How often lows happened in trials depended on the rest of the treatment. With Awiqli as the only insulin, roughly 9 to 14 percent of people had at least one reading below 54 mg/dL (the level considered a clinically significant low) over six months to a year. Among people also taking mealtime insulin, about half did. Severe lows, where someone needs another person's help to recover, were uncommon. If someone passes out, has a seizure or is too confused to eat or drink safely, others should give glucagon if it has been prescribed and call 911. Other common effects include redness or itching where the injection was given, rash, swelling of the hands and feet, and weight gain. Repeated injections into one spot can leave pitted, thickened or lumpy skin, and insulin injected there may be absorbed unpredictably. When blood sugar improves quickly, some people notice temporarily blurred vision, and existing diabetic eye disease or nerve pain can briefly get worse. Rarely, insulin causes a severe whole-body allergic reaction. Stop Awiqli and call 911 for trouble breathing, swelling of the face, tongue or throat, or a rash over the whole body.

Interactions & Warnings

Many medicines shift blood sugar and can change how much insulin is needed. Other diabetes medicines, including GLP-1 medicines and SGLT2 inhibitors (diabetes pills that help the kidneys remove sugar in urine), can add to the risk of lows. Corticosteroids such as prednisone, some antipsychotic medicines and some hormones, including birth control pills, can push blood sugar higher. Beta-blockers, which treat high blood pressure and heart conditions, can hide the warning signs of a low. Alcohol can make blood sugar harder to predict. Tell the prescriber and pharmacist about any new prescription, over-the-counter medicine or supplement, and check blood sugar more often after a change. Taking insulin with pioglitazone (Actos), a diabetes pill in the thiazolidinedione (TZD) group, can cause fluid buildup and heart failure. Report new shortness of breath, swelling of the ankles or feet, or sudden weight gain to the care team. Insulin moves potassium from the blood into cells and can lower potassium levels. Low potassium can cause muscle weakness and, when severe, dangerous heart rhythm problems. People who also take a medicine that lowers potassium, such as a diuretic (water pill) like furosemide or hydrochlorothiazide, should make sure the prescriber knows, since potassium blood tests may be needed. Never share a pen with anyone, even with a new needle, because it can spread blood-borne infections. There are no data on Awiqli in pregnancy or breastfeeding. Poorly controlled diabetes carries its own risks in pregnancy, so anyone pregnant or planning a pregnancy should review their insulin plan with the care team.

What to Expect

Awiqli takes two to four weeks of regular doses to reach a steady effect, so blood sugar is checked more often at the start and after switching, and the dose is adjusted gradually from week to week. In trials, people starting insulin with Awiqli lowered their HbA1c (a blood test reflecting average blood sugar over roughly three months) by about 1.5 percentage points, from around 8.5% to about 7%, slightly more than people on daily glargine or degludec. People switching from a daily basal insulin did slightly better, or about the same when they also used mealtime insulin. The main practical gain is fewer injections: 52 basal insulin injections a year instead of 365. The trade-off is less room to fine-tune. A daily dose can be lowered tomorrow, but a weekly dose keeps working for days, so lows may linger and a dose change takes time to show. A continuous glucose monitor or regular fingerstick checks remain part of the routine. Like other diabetes treatment, it is usually long term. Contact the care team if lows are frequent or come without warning signs, or if readings keep running above target, since the dose or other medicines may need to change.

Questions to Ask Your Doctor

  1. 1.Is a once-weekly insulin a good fit for me compared with a daily basal insulin?
  2. 2.How will we switch from my current insulin, and how often should I check my blood sugar in the first month?
  3. 3.Should any of my other diabetes medicines be lowered when I start Awiqli?
  4. 4.What should I do for a low, and should I keep glucagon at home?
  5. 5.How should I handle a missed dose, a sick day or a change in my injection day?

Last reviewed • Oct 2026

Educational content, not medical advice.